Reliving an Inspiring Experience – From Physicians to Physicians.
Highlights from our latest Cardionovum® Workshop at IRCCS Policlinico San Donato, a international event by physicians, for physicians.
With over 40 participants from around the world, the workshop brought together leading experts to exchange clinical experience, insights, and innovation in the use of drug-coated balloon in interventional cardiology.
This workshop once again showcased the power of collaboration and education in advancing patient care.
Cardionovum® is proud to announce a major milestone: For the approval by ANVISA, the Brazilian Health Regulatory Agency, of Aperto® OTW DCB for commercial use in Brazil. This approval enables Brazilian patients undergoing dialysis to benefit from a therapy that extends the lifespan of their arteriovenous fistulas, thereby improving both quality of life and treatment outcomes.
Cardionovum® is proud to announce that the“APERTO 600” study, evaluating the efficacy of the Aperto® OTW DCB in vascular access occlusion management, has been published in the Journal of Vascular Access under the title: “Real-World Outcomes of 600 Drug-Coated Balloon Angioplasties.”
At EuroPCR 2025, Dr. Aloke Finn and Prof. Antonio Colombo discussed the under-recognized issue of particulate embolization after drug-coated balloon (DCB) angioplasty.
They clarified its distinction from traditional distal embolization and underscored its iatrogenic nature—originating from the device, not plaque or thrombus. The conversation highlighted that particle size, carrier type, and coating technology, particularly crystalline-like coatings, play key roles in downstream safety.
While not universally problematic, embolization may be relevant for specific patients or devices. They stressed the need to translate preclinical insights into clinical practice and to innovate DCB technologies that balance safety with efficacy.
Prof. Matteo Tozzi (Varese, Italy) spoke to Vascular News about his extensive experience with drug-coated balloons (DCBs) in vascular access, particularly the Aperto® OTW DCB by Cardionovum®.
Having used over 600 DCBs in the past decade, Tozzi emphasized the superior efficacy of Aperto® OTW compared to plain balloon angioplasty (POBA).
To address the lack of economic data, he has initiated an analysis to evaluate the cost-effectiveness of DCBs in treating vascular access failure: based on the findings of his study named Aperto 600, Tozzi advocates for DCBs to be considered a “first-line treatment” for stenosis and vascular access failure in haemodialysis patients.
